@istanbullulab
Medicinal chemistry lab @IKCU, Faculty of Pharmacy, Izmir. Drug discovery studies; design and synthesis new compounds as antileishmanial, antibacterial, anticancer, antiparasitic, FABPi, TYK2i @istanbulluh.bsky.social @huseyinkosker.bsky.social
Please RT:
We have an opening for a junior group leader position in „Phage Biology & Biotechnology“.
www.fz-juelich.de/de/karriere/...
Interested candidates are encouraged to contact me via email for further details.
@spp2330.bsky.social; @mibinet.bsky.social
Spreading the results of @costprogramme.bsky.social Action networks to different target audiences is crucial. That’s why we’re focusing this week on mastering social media. Starting today with our Science Communication Coordinators. Thanks to all for joining us for the #COSTAcademy training! 😊
We're pleased to share our latest paper, published in Drug and Drug candidates titled "Probing Redox Responses and DNA Interactions in Drug Discovery"
@istanbulluh.bsky.social
@huseyinkosker.bsky.social
Our project entitled ‘Synthesis and biological activities of antimycobacterial effective pyrrolamide derivatives’has been entitled to support within the scope of TÜBİTAK 2209-A Research Projects Support Programme for Undergraduate Students 2024/1
@istanbulluh.bsky.social
@huseyinkosker.bsky.social
Our project entitled ‘Synthesis and biological activities of antimycobacterial effective pyrrolamide derivatives’has been entitled to support within the scope of TÜBİTAK 2209-A Research Projects Support Programme for Undergraduate Students 2024/1
@istanbulluh.bsky.social
@huseyinkosker.bsky.social
hoşgeldiniz hocam
We're excited to share our latest paper, published in ChemBiodiv titled ‘Novel Triazolopyrimidinone Compounds as Adipocyte Fatty Acid Binding Protein (FABP4) Inhibitors’
doi.org/10.1002/cbdv...
@istanbulluh.bsky.social
@huseyinkosker.bsky.social
We're excited to share our latest paper, published in ChemBiodiv titled ‘Novel Triazolopyrimidinone Compounds as Adipocyte Fatty Acid Binding Protein (FABP4) Inhibitors’
doi.org/10.1002/cbdv...
@istanbulluh.bsky.social
@huseyinkosker.bsky.social
Our project, submitted to the TUBITAK-2515 programme within the COST-CA21111 action "One Health drugs against parasitic vector borne diseases in Europe and beyond (OneHealthDrugs)", was eligible for funding.
@istanbulluh.bsky.social
@huseyinkosker.bsky.social
Looking for a PostDoc outside the UK to apply with me for a fully funded 2-year postdoc in electrosynthesis! #Newton
📩 No generic emails! Instead, tell me:
🔹 Your research & key contributions
🔹 How our expertise complements each other
Let’s chat! ⚡ RT & tag potential candidates! #ChemSky
The Hit to Lead process is an integral part of contemporary drug discovery.
A perspective just published in #ChemMedChem (@chemistryeurope.bsky.social), highlight the new set of @euromedchem.bsky.social best practices focused on H2L.
chemistry-europe.onlinelibrary.wiley.com/doi/10.1002/...
Within the scope of TÜBİTAK-1001-2024-2; our project entitled "Synthesis of new thiazolopyrimidine pyrrolimide derivatives as DNA GyraseB inhibitor antibacterial agents and evaluation of their biological activities" was found eligible for support
@istanbulluh.bsky.social
@huseyinkosker.bsky.social
Join our research team!
We have a Postdoctoral Fellowship opening on diamond-based quantum networks.
Deadline is March 12th!
Follow the link for details!
#quantum #optics #spin #photon #physics #diamond #research #vacancy #postdoc
www.jobs.cam.ac.uk/job/50162/
Postdoctoral Researcher on Quantum Networks using Diamond Spin Qubits, University of Cambridge
#QuantumNetworks #QuantumMemory #QuantumOptics
www.quantiki.org/position/pos...
👀 In case you missed it...here’s a sneak peek into Guinea’s incredible journey to eliminate #SleepingSickness as a public health problem!
📽️ Watch the full film to see how Guinea achieved this milestone: youtube.com/watch?v=csdn...
#BeatNTDs
Very interesting to see the 50 new drugs that made it to FDA approval in 2024 in one place. A lot of really exciting small molecule chemistry with interesting functional groups, deuterations and covalent warheads. #chemsky #chembio
www.linkedin.com/posts/chrisd...
A 2-yr postdoc is available in our group! The successful candidate will have a strong background in organic synthesis and <6 years after a PhD. The research will focus on novel mechanochemical organic reactions. Questions/applications: email Lukasz (address in the pic). Deadline: 7th March 2025.
New PhD/PostDoc positions in Machine Learning for Quantum Computing and Simulation of Quantum Matter:
dobrautz.github.io/jobs/postdoc...
dobrautz.github.io/jobs/phd/cas...
Sharing and endorsing would be really appreciated <3
@hzdr.bsky.social @scadsai.bsky.social @tudresden.bsky.social
Who wants to come and work with our group @oxfordchemistry.bsky.social on photoswitches and photopharmacology 🙋♀️🙋🏻🙋♂️
Apply for our open #chempostdoc position now! Deadline 28th Feb. Reposts appreciated #Chemsky
my.corehr.com/pls/uoxrecru...
#PostDoc opportunity in synthesis of small ring hydrocarbons and heterocycles at University of Oxford (UK) ref: 177884 | duration: 48 months | start: before 01-Jul-2025 | closing: 02-Mar-2025 #SynChem #ChemPostDoc #PostDocJobs #UKChemJobs #chemsky 🧪
my.corehr.com/pls/uoxrecru...
#chempostdoc
Boehringer's investigational idiopathic pulmonary fibrosis (IPF) drug nerandomilast had a "second phase 3 win" leading the company to expand the indications it will seek FDA approval for. FIBRONEER-ILD trial for progressive pulmonary fibrosis (PPF): www.fiercebiotech.com/biotech/boeh... #medsky
Our first contribution in J. Med. Chem; does this make us bona fide med chemists now? Check out this latest study on countering Parkinsonism by Drs. @rahuldjana.bsky.social, Nguyen, and Yan, and Prof. Chen!
Link: pubs.acs.org/doi/10.1021/...
If you work in drug discovery and you read one thing this weekend, make it this exceptional J Med Chem editorial. Hits on almost every blessed thing I’ve tweetorialized over the last several years.
Quantitation and Error Measurements in Dose–Response Curves
In 2007, John Van Drie wrote a very insightful article about what the fields of drug discovery and CADD might hold for us in the next 20 years. Since we are almost at the 20-year mark, I assess how well those predictions have held up (promisingly, I think) medchemash.substack.com/p/drug-disco...
Concluding remarks by Claudia Höbartner at #EFMCISCB25. Thanks to sponsors, exhibitors, committees, secretariat and, above all, participants that made this event a very successful one. See you again in 2027!
@euromedchem.bsky.social
@youngscinet.bsky.social
Join us in Vienna 8-9 May for the #Ubiquitin & Friends Symposium 2025! Excellent line-up of guest speakers👇And many slots for talks from abstracts, plus flash-talks & posters! Lots of opportunities to network with peers & experts in a friendly atmosphere! ➡️ www.protein-degradation.org/symposium/
LAST CHANCE TO JOIN @euromedchem.bsky.social EFMC-ISCB 2025!
Do not miss this key event in chemical biology, already attracting over 225 participants! (www.efmc-iscb.org/speakers)
Day pass available. Register Now! (www.efmc-iscb.org/registration)
#EFMCISCB25
@youngscinet.bsky.social
And finally the #EFMCISCB25 is starting, opened by Uwe Grether, co-chair of the event together with Claudia Hobartner.
@euromedchem.bsky.social
The proteins on the surface our cells are key to many important signalling pathways.
In an amazing lecture at #EFMCISCB25, @berndwollscheid.bsky.social talked about his group's exciting research into better understanding the cell surfaceome at various levels. (1/4)
